公开(公告)号：US20180117059A1

公开(公告)日：2018-05-03

申请号：US15574347

申请日：2016-05-12

Applicant: Novartis AG

Inventor： NgocDiep LE ,  Gerald LELAIS ,  Yong JIA

IPC: A61K31/55 ,  A61P35/00

CPC classification number: A61K31/55 ,  A61P35/00

Abstract: Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del) the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.

公开(公告)号：US20210100812A1

公开(公告)日：2021-04-08

申请号：US17108728

申请日：2020-12-01

Applicant: NOVARTIS AG

Inventor： NgocDiep LE ,  Gerald LELAIS ,  Yong JIA

IPC: A61K31/55 ,  A61P35/00

Abstract: Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del), the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.